Showing results (131-140 of 246) with videos related to

Sort By:
Pageof 25
The Journal of Clinical Investigation|March 17, 2026
Targeting Wnt/β-Catenin and circadian regulator restores PRC2/EZH2 controlled chromatin bivalency and suppresses cell state diversityYatian Yang, Xiong Zhang, Varadha Balaji Venkadakrishnan, et al.
Cancer Research|June 30, 2022
CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2Haoyan Li, Yin Wang, Kevin Lin, et al.
Cancer Discovery|October 28, 2016
The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate CancerJennifer L Bishop, Daksh Thaper, Sepideh Vahid, et al.
Nature|July 28, 2018
Suppression of insulin feedback enhances the efficacy of PI3K inhibitorsBenjamin D Hopkins, Chantal Pauli, Xing Du, et al.
Molecular Oncology|March 1, 2022
The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapyJohannes C van der Mijn, Kenneth W Eng, Pooja Chandra, et al.
European Urology|August 7, 2025
Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate CancerSusan Halabi, Siyuan Guo, Bin Luo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate CancerBo Liu, Likun Li, Guang Yang, et al.
Cancer Cell|October 12, 2016
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate CancerEtienne Dardenne, Himisha Beltran, Matteo Benelli, et al.
European Urology Oncology|November 15, 2024
Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate CancerPraful Ravi, Caiwei Zhong, Wanling Xie, et al.
Nature Medicine|February 9, 2016
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancerHimisha Beltran, Davide Prandi, Juan Miguel Mosquera, et al.
Pageof 25